Blockade of Nociceptin/Orphanin FQ Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior

A multidisciplinary approach was followed to investigate whether the opioid-like peptide nociceptin/orphanin FQ (N/OFQ) regulates the nigrostriatal dopaminergic pathway and motor behavior. Nigrostriatal dopaminergic cells, which express N/OFQ peptide (NOP) receptors, are located in the substantia nigra pars compacta and extend their dendrites in the substantia nigra pars reticulata, thereby modulating the basal ganglia output neurons. In vitro electrophysiological recordings demonstrated that N/OFQ hyperpolarized the dopaminergic cells of the substantia nigra pars compacta and inhibited their firing activity. In vivo dual-probe microdialysis showed that N/OFQ perfused in the substantia nigra pars reticulata reduced dopamine release in the ipsilateral striatum, whereas UFP-101 ([Nphe1,Arg14,Lys15]N/OFQ(1-13)-NH2) (a selective NOP receptor peptide antagonist) stimulated it. N/OFQ microinjected in the substantia nigra pars reticulata impaired rat performance on a rotarod apparatus, whereas UFP-101 enhanced it. Electromyography revealed that N/OFQ and UFP-101 oppositely affected muscle tone, inducing relaxation and contraction of triceps, respectively. The selective NOP receptor nonpeptide antagonist J-113397 (1-[3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one), either injected intranigrally or given systemically, also elevated striatal dopamine release and facilitated motor activity, confirming that these effects were caused by blockade of endogenous N/OFQ signaling. The inhibitory role played by endogenous N/OFQ on motor activity was additionally strengthened by the finding that mice lacking the NOP receptor gene outperformed wild-type mice on the rotarod. We conclude that NOP receptors in the substantia nigra pars reticulata, activated by endogenous N/OFQ, drive a physiologically inhibitory control on motor behavior, possibly via modulation of the nigrostriatal dopaminergic pathway.

[1]  H. Takeshima,et al.  Exogenous, but not endogenous nociceptin modulates mesolimbic dopamine release in mice , 2004, Journal of neurochemistry.

[2]  B. Westerink,et al.  Tonic inhibition by orphanin FQ/nociceptin of noradrenaline neurotransmission in the amygdala. , 2004, European journal of pharmacology.

[3]  M. Scheideler,et al.  Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[4]  L. Terenius,et al.  Evidence in locomotion test for the functional heterogeneity of ORL‐1 receptors , 2004, British journal of pharmacology.

[5]  N. Zaveri.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. , 2003, Life sciences.

[6]  F. Bergquist,et al.  Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod , 2003, Brain Research.

[7]  J. Crabbe,et al.  Influence of task parameters on rotarod performance and sensitivity to ethanol in mice , 2003, Behavioural Brain Research.

[8]  R. Bertorelli,et al.  Blockade of nociceptin/orphanin FQ–NOP receptor signalling produces antidepressant‐like effects: pharmacological and genetic evidences from the mouse forced swimming test , 2003, The European journal of neuroscience.

[9]  D. Lambert,et al.  Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5‐hydroxytryptamine and noradrenaline release in the rat neocortex , 2003, British journal of pharmacology.

[10]  M. Kathmann,et al.  Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors , 2002, British journal of pharmacology.

[11]  M. Morari,et al.  Striatal dopamine–NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors , 2002, Journal of neurochemistry.

[12]  N. Maidment,et al.  Heroin-induced locomotion and mesolimbic dopamine release is unchanged in mice lacking the ORL.1 receptor gene , 2002, Brain Research.

[13]  E. Ongini,et al.  Lack of the nociceptin receptor does not affect acute or chronic nociception in mice , 2002, Peptides.

[14]  N. Maidment,et al.  Orphanin FQ/nociceptin blocks cocaine-induced behavioral sensitization in rats , 2002, Psychopharmacology.

[15]  Steven W. Johnson,et al.  Actions of orphanin FQ/nociceptin on rat ventral tegmental area neurons in vitro , 2002, British journal of pharmacology.

[16]  A. Tan,et al.  Rat ventral midbrain dopamine neurons express the orphanin FQ/nociceptin receptor ORL-1 , 2002, Neuroreport.

[17]  M. Morari,et al.  Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat , 2002, Neuroscience.

[18]  S. Salvadori,et al.  [Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor , 2002, British journal of pharmacology.

[19]  H. Akil,et al.  Nociceptin/orphanin FQ and opioid receptor‐like receptor mRNA expression in dopamine systems , 2002, The Journal of comparative neurology.

[20]  R. Quirion,et al.  Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  G. Pasternak,et al.  The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. , 2001, Pharmacological reviews.

[22]  G. Calo’,et al.  Inhibitory action of nociceptin/orphanin FQ on functionally different thalamic neurons in urethane‐anaesthetized rats , 2001, British journal of pharmacology.

[23]  C. Trapella,et al.  A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist.. , 2001, Bioorganic & medicinal chemistry.

[24]  R. Egan,et al.  Nociceptin inhibits cough in the guinea‐pig by activation of ORL1 receptors , 2001, British journal of pharmacology.

[25]  N. Maidment,et al.  Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats , 2001, Psychopharmacology.

[26]  S. Salvadori,et al.  Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[27]  H. Ueda,et al.  Enhanced Spinal Nociceptin Receptor Expression Develops Morphine Tolerance and Dependence , 2000, The Journal of Neuroscience.

[28]  S. Salvadori,et al.  Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. , 2000, Journal of medicinal chemistry.

[29]  S. Pieretti,et al.  Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats , 2000, Peptides.

[30]  S. Candeletti,et al.  Effects of an antisense oligonucleotide to pronociceptin and long-term prevention of morphine actions by nociceptin , 2000, Peptides.

[31]  G. Adam,et al.  A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Salvadori,et al.  Pharmacology of nociceptin and its receptor: a novel therapeutic target , 2000, British journal of pharmacology.

[33]  C. Polidori,et al.  Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist , 2000, Psychopharmacology.

[34]  Y. Iwasawa,et al.  A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397. , 2000, European journal of pharmacology.

[35]  Y. Iwasawa,et al.  Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). , 1999, Journal of medicinal chemistry.

[36]  P. Shepard,et al.  Pertussis Toxin Lesions of the Rat Substantia Nigra Block the Inhibitory Effects of the γ-Hydroxybutyrate Agent, S(-)HA-966 without Affecting the Basal Firing Properties of Dopamine Neurons , 1999, Neuropsychopharmacology.

[37]  A. Loizzo,et al.  Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats , 1999, Neuroscience Letters.

[38]  N. Maidment,et al.  Orphanin FQ/Nociceptin Modulation of Mesolimbic Dopamine Transmission Determined by Microdialysis , 1999, Journal of neurochemistry.

[39]  J. Tepper,et al.  GABAA and GABAB antagonists differentially affect the firing pattern of substantia nigra dopaminergic neurons in vivo , 1999, Synapse.

[40]  K. Shieh,et al.  Ontogeny of the Diurnal Rhythm of Tuberoinfundibular Dopaminergic Neuronal Activity in Peripubertal Female Rats: Possible Involvement of Cholinergic and Opioidergic Systems , 1998, Neuroendocrinology.

[41]  T. Manabe,et al.  Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors , 1998, Nature.

[42]  T. Nabeshima,et al.  Loss of Antinociception Induced by Naloxone Benzoylhydrazone in Nociceptin Receptor-Knockout Mice* , 1998, The Journal of Biological Chemistry.

[43]  J. Labandeira-Garcia,et al.  An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. , 1997, Brain research. Brain research protocols.

[44]  B. Bontempi,et al.  Systemic Morphine-Induced Fos Protein in the Rat Striatum and Nucleus Accumbens Is Regulated by μ Opioid Receptors in the Substantia Nigra and Ventral Tegmental Area , 1997, The Journal of Neuroscience.

[45]  J. Kuno,et al.  Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor , 1997, The EMBO journal.

[46]  F. Monsma,et al.  Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ , 1996, Neurochemical Research.

[47]  N. Maidment,et al.  Intracerebroventricular orphanin FQ/Nociceptin supresses dopamine release in the nucleus accumbens of anaesthetized rats , 1996, Neuroscience.

[48]  M. L. Pucak,et al.  Effects of haloperidol on the activity and membrane physiology of substantia nigra dopamine neurons recorded in vitro , 1996, Brain Research.

[49]  D. Grandy,et al.  Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor , 1995, Science.

[50]  Marc Parmentier,et al.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor , 1995, Nature.

[51]  P. Calabresi,et al.  Properties of the Hyperpolarization‐activated Cation Current lh in Rat Midbrain Dopaminergic Neurons , 1995, The European journal of neuroscience.

[52]  Stanley J. Watson,et al.  Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications , 1995, Trends in Neurosciences.

[53]  J. Walker,et al.  Rotational behavior mediated by dopaminergic and nondopaminergic mechanisms after intranigral microinjection of specific mu, delta and kappa opioid agonists. , 1988, The Journal of pharmacology and experimental therapeutics.

[54]  N. Mercuri,et al.  Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. , 1987, The Journal of physiology.

[55]  G. Chiara,et al.  Non-dopaminergic mechanisms in the turning behavior evoked by intranigral opiates , 1985, Brain Research.

[56]  R. Pinnock.  The actions of antipsychotic drugs on dopamine receptors in the rat substantia nigra , 1984, British journal of pharmacology.

[57]  L. Turski,et al.  The role of the substantia nigra in motility of the rat Muscular rigidity, body asymmetry and catalepsy after injection of morphine into the nigra , 1983, Neuropharmacology.

[58]  L. Turski,et al.  Disinhibition of nigral GABA output neurons mediates muscular rigidity elicited by striatal opioid receptor stimulation. , 1982, Life sciences.

[59]  F. Buchthal,et al.  Nerve conduction, tactile sensibility, and the electromyogram after suture or compression of peripheral nerve: a longitudinal study in man. , 1979, Journal of neurology, neurosurgery, and psychiatry.

[60]  E. Way,et al.  Circling behavior and stereotypy induced by intranigral opiate microinjections. , 1977, The Journal of pharmacology and experimental therapeutics.

[61]  Babu Subramanyam,et al.  MONITORING MOLECULES IN NEUROSCIENCE , 1991 .

[62]  P. Calabresi,et al.  Effects of glycine on neurons in the rat substantia nigra zona compacta: In vitro electrophysiological study , 1990, Synapse.

[63]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .